Qualitative OCT biomarkers for visual improvement in treatment of diabetic macular edema

---

Original Article

Author Details : Natasha Radhakrishnan*, Gopal S Pillai, Aishwarya Iyer

Volume : 8, Issue : 3, Year : 2022

Article Page : 205-209

https://doi.org/10.18231/j.ijooo.2022.046

Suggest article by email

Get Permission

---

Abstract

Purpose: To identify baseline qualitatative OCT biomarkers that can predict good visual outcome in diabetic macular edema after treatment.
Study design: Prospective, observational study in the time period.
Materials and Methods: We included 37 eyes of 37 patients with treatment naïve diabetic macular edema who subsequently underwent treatment with injections of intravitreal Ranibizumab. Inclusion criteria was: Presenting vision < 0>250 microns). 3 injections were given monthly irrespective of treatment response followed by PRN dosing. Factors under evaluation were: 1) Submacular detachment (SMD) (2) cystoid changes in the inner and outer nuclear layer (4) Integrity of IS-OS junction. (5) Hyper Reflective Foci(HRF) and location (6) vitreomacular interface (7) Disruption of inner retinal layers(DRIL)
Results: We included 37 eyes in our study. For analysis, based on final visual acuity patients were divided in two groups: (1) Group A: Good visual acuity (>10 ETDRS letter gain) and (2) Group B: Poor visual outcome (< 10> Conclusion: Presence of SMD was found to have most significance in predicting good visual acuity response to anti VEGF.DRIL was found to decrease during the treatment but a predictive role could not be demonstrated.
 
Keywords: Diabetic maculopathy, Diabetic macular edema, OCT biomarkers

How to cite : Radhakrishnan N, Pillai G S, Iyer A, Qualitative OCT biomarkers for visual improvement in treatment of diabetic macular edema. IP Int J Ocul Oncol Oculoplasty 2022;8(3):205-209

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.